Epix Pharmaceuticals (NASDAQ: [[ticker:EPIX]]) said today it has resubmitted an application to the Food and Drug Administration for marketing of Vasovist, and hopes to win approval to market the product in the U.S. by the end of 2008. The Lexington, MA-based company’s original application was filed in December 2003, and has been delayed by regulators’ questions and an appeal process. The product, Epix’s first in the U.S. if cleared for sale, is designed to help doctors get a clearer picture from magnetic resonance angiography tests to look at patients’ blood vessels.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
